1T-LSD (N1-(thiophene-2-carbonyl)-lysergic acid diethylamide, SYN-L-021) is an acylated derivative of lysergic acid diethylamide (LSD), which has been sold as a designer drug. It was first identified in Japan in 2023 on blotter paper misrepresented as containing 1D-LSD, but which on analysis was determined to contain 1T-LSD instead.[1] It was also detected in Germany around the same time.[2]
 | |
| Clinical data | |
|---|---|
| Routes of administration | By mouth, under the tongue |
| Identifiers | |
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C25H27N3O2S |
| Molar mass | 433.57 g·mol−1 |
| 3D model (JSmol) | |
| |
See also
editReferences
edit- ^ Okada Y, Ueno K, Nishiwaki N, Nishimura T, Segawa H, Yamamuro T, et al. (July 2023). "Identification of 1-(thiophene-2-carbonyl)-LSD from blotter paper falsely labeled "1D-LSD"". Forensic Toxicology. doi:10.1007/s11419-023-00668-8. PMID 37421500. S2CID 259374662.
- ^ "New psychoactive substances - the current situation in Europe" (PDF). European Drug Report. European Union Drugs Agency (EUDA). 2024.
 | This hallucinogen-related article is a stub. You can help Wikipedia by expanding it. |